
AMENDMENTS TO THE CLAIMS

1-20 (canceled).

21. (Currently Amended) A compound of formula III



(III)

wherein R_1 and R_2 are independently hydrogen, straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, branched C_{1-6} alkyl group optionally substituted with a phenyl group, or R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms ~~heteroatom~~, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a ~~phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro, or halogen, or is a~~ 5-6 membered N-containing heteroaromatic ring ~~containing at least one heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur, wherein the nitrogen heteroatom is optionally~~ having a [[an]] N-oxide structure on the nitrogen heteroatom;

n is 0, 1, or 2;

z is 0 or 1;

~~with the proviso that~~

~~if R_1 and R_2 independently represent a hydrogen atom, a straight chained C_{1-6} alkyl group optionally substituted with a phenyl group, a branched C_{1-6} alkyl group optionally substituted with a phenyl group, or together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, then A is a heteroaromatic ring containing oxygen or sulfur heteroatom or an N-containing heteroaromatic ring having an N-oxide structure on the nitrogen heteroatom and~~

~~if A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl or nitro groups or halogen, or is a 5-6 membered N-containing heteroaromatic ring, then R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo, or benzyl groups;~~

or a stereoisomer or salt thereof.

22-26. (Canceled)

27. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-l,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

28-29. (Canceled)

30. (Previously Presented) The compound according to claim 27, wherein the compound is (+)-5,6-dihydro-5-[(1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-l,2,4-oxadiazine, or a stereoisomer and/or salt thereof.


31. (Previously Presented) The compound according to claim 21, wherein the compound is 5,6-dihydro-5-[(1-oxido-1-piperidinyl)methyl]-3-(1-oxido-3-pyridyl)-4H-l,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

32-34. (Canceled)

35. (Previously Presented) A pharmaceutical composition comprising a compound of formula III as defined in claim 21 and a pharmaceutically acceptable carrier.

36-37. (Canceled)

38. (New) A compound of formula III



(III)

wherein R_1 and R_2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatom, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C_{1-4} alkyl, C_{1-4} haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein the nitrogen heteroatom optionally has a N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

or a stereoisomer or salt thereof.

39. (New) The compound according to claim 38, wherein the compound is 5,6-dihydro-5-[(4-benzyl-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

40. (New) The compound according to claim 38, wherein the compound is 5,6-dihydro-5-[(2-oxo-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

41. (New) The compound according to claim 38, wherein the compound is 5,6-dihydro-5-[(4-hydroxy-1-piperidinyl)methyl]-3-(3-pyridyl)-4H-1,2,4-oxadiazine, or a stereoisomer and/or salt thereof.

42. (New) A pharmaceutical composition comprising a compound of formula III as defined in claim 38 and a pharmaceutically acceptable carrier.